Overview

AB122 Platform Study

Status:
Recruiting

Trial end date:
2024-05-01

Target enrollment:

Participant gender:

Summary

This is a phase 1, non-randomized open-label, multicenter platform study designed to evaluate the tolerability and safety of AB122 in patients with malignancies specified in each cohort.

Phase:

Phase 1

Details

Lead Sponsor:

Taiho Pharmaceutical Co., Ltd.